3 Stocks Pushing The Drugs Industry Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

One out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 29 points (-0.2%) at 16,367 as of Wednesday, March 5, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,229 issues advancing vs. 1,681 declining with 174 unchanged.

The Drugs industry currently sits up 0.2% versus the S&P 500, which is unchanged. On the negative front, top decliners within the industry include XOMA ( XOMA), down 26.1%, Endo International ( ENDP), down 3.6%, Jazz Pharmaceuticals ( JAZZ), down 2.3%, Biomarin Pharmaceutical ( BMRN), down 1.8% and Shire ( SHPG), down 1.4%. Top gainers within the industry include Arrowhead Research Corporation ( ARWR), up 23.8%, Teva Pharmaceutical Industries ( TEVA), up 1.0% and Novartis ( NVS), up 0.8%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Eli Lilly and Company ( LLY) is one of the companies pushing the Drugs industry lower today. As of noon trading, Eli Lilly and Company is down $0.58 (-1.0%) to $59.26 on light volume. Thus far, 1.1 million shares of Eli Lilly and Company exchanged hands as compared to its average daily volume of 5.6 million shares. The stock has ranged in price between $59.22-$59.97 after having opened the day at $59.94 as compared to the previous trading day's close of $59.85.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. It operates in two segments, Human Pharmaceutical Products and Animal Health Products. Eli Lilly and Company has a market cap of $66.1 billion and is part of the health care sector. Shares are up 15.8% year-to-date as of the close of trading on Tuesday. Currently there are 5 analysts that rate Eli Lilly and Company a buy, 4 analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Eli Lilly and Company as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, reasonable valuation levels, good cash flow from operations, increase in stock price during the past year and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Eli Lilly and Company Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

Eli Lilly Still Looking for Lower Prices

Is Lilly Headed for the Valley?

Walmart, With Extra $10M Fund, Is Among 7 Giving for Hurricane Irma Relief